Research ExplorerPublications6q deletion is frequent but unrelated to patient prognosis i...

6q deletion is frequent but unrelated to patient prognosis in breast cancer

Standard

6q deletion is frequent but unrelated to patient prognosis in breast cancer. / Lebok, Patrick; Bönte, Hannah; Kluth, Martina; Möller-Koop, Christina; Witzel, Isabell; Wölber, Linn; Paluchowski, Peter; Wilke, Christian; Heilenkötter, Uwe; Müller, Volkmar; Schmalfeldt, Barbara; Simon, Ronald; Sauter, Guido; Terracciano, Luigi; Krech, Rainer Horst; von der Assen, Albert; Burandt, Eike.

In: BREAST CANCER-TOKYO, Vol. 29, No. 2, 03.2022, p. 216-223.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lebok, P, Bönte, H, Kluth, M, Möller-Koop, C, Witzel, I, Wölber, L, Paluchowski, P, Wilke, C, Heilenkötter, U, Müller, V, Schmalfeldt, B, Simon, R, Sauter, G, Terracciano, L, Krech, RH, von der Assen, A & Burandt, E 2022, '6q deletion is frequent but unrelated to patient prognosis in breast cancer', BREAST CANCER-TOKYO, vol. 29, no. 2, pp. 216-223. https://doi.org/10.1007/s12282-021-01301-5

APA

Lebok, P., Bönte, H., Kluth, M., Möller-Koop, C., Witzel, I., Wölber, L., Paluchowski, P., Wilke, C., Heilenkötter, U., Müller, V., Schmalfeldt, B., Simon, R., Sauter, G., Terracciano, L., Krech, R. H., von der Assen, A., & Burandt, E. (2022). 6q deletion is frequent but unrelated to patient prognosis in breast cancer. BREAST CANCER-TOKYO, 29(2), 216-223. https://doi.org/10.1007/s12282-021-01301-5

Vancouver

Lebok P, Bönte H, Kluth M, Möller-Koop C, Witzel I, Wölber L et al. 6q deletion is frequent but unrelated to patient prognosis in breast cancer. BREAST CANCER-TOKYO. 2022 Mar;29(2):216-223. https://doi.org/10.1007/s12282-021-01301-5

Bibtex

@article{524139beed654289bae1b58d701f606c,
title = "6q deletion is frequent but unrelated to patient prognosis in breast cancer",
abstract = "BACKGROUND: Deletions involving the long arm of chromosome 6 have been reported to occur in breast cancer, but little is known about the clinical relevance of this alteration.METHODS: We made use of a pre-existing tissue microarray with 2197 breast cancers and employed a 6q15/centromere 6 dual-labeling probe for fluorescence in situ (FISH) analysis RESULTS: Heterozygous 6q15 deletions were found in 202 (18%) of 1099 interpretable cancers, including 19% of 804 cancers of no special type (NST), 3% of 29 lobular cancers, 7% of 41 cribriform cancers, and 28% of 18 cancers with papillary features. Homozygous deletions were not detected. In the largest subset of NST tumors, 6q15 deletions were significantly linked to advanced tumor stage and high grade (p < 0.0001 each). 6q deletions were also associated with estrogen receptor negativity (p = 0.0182), high Ki67 proliferation index (p < 0.0001), amplifications of HER2 (p = 0.0159), CCND1 (p = 0.0069), and cMYC (p = 0.0411), as well as deletions of PTEN (p = 0.0003), 8p21 (p < 0.0001), and 9p21 (p = 0.0179). However, 6q15 deletion was unrelated to patient survival in all cancers, in NST cancers, or in subsets of cancers defined by the presence or absence of lymph-node metastases.CONCLUSION: Our data demonstrate that 6q deletion is a frequent event in breast cancer that is statistically linked to unfavorable tumor phenotype and features of genomic instability. The absence of any prognostic impact argues against a clinical applicability of 6q15 deletion testing in breast cancer patients.",
author = "Patrick Lebok and Hannah B{\"o}nte and Martina Kluth and Christina M{\"o}ller-Koop and Isabell Witzel and Linn W{\"o}lber and Peter Paluchowski and Christian Wilke and Uwe Heilenk{\"o}tter and Volkmar M{\"u}ller and Barbara Schmalfeldt and Ronald Simon and Guido Sauter and Luigi Terracciano and Krech, {Rainer Horst} and {von der Assen}, Albert and Eike Burandt",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = mar,
doi = "10.1007/s12282-021-01301-5",
language = "English",
volume = "29",
pages = "216--223",
journal = "BREAST CANCER-TOKYO",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

RIS

TY - JOUR

T1 - 6q deletion is frequent but unrelated to patient prognosis in breast cancer

AU - Lebok, Patrick

AU - Bönte, Hannah

AU - Kluth, Martina

AU - Möller-Koop, Christina

AU - Witzel, Isabell

AU - Wölber, Linn

AU - Paluchowski, Peter

AU - Wilke, Christian

AU - Heilenkötter, Uwe

AU - Müller, Volkmar

AU - Schmalfeldt, Barbara

AU - Simon, Ronald

AU - Sauter, Guido

AU - Terracciano, Luigi

AU - Krech, Rainer Horst

AU - von der Assen, Albert

AU - Burandt, Eike

N1 - © 2021. The Author(s).

PY - 2022/3

Y1 - 2022/3

N2 - BACKGROUND: Deletions involving the long arm of chromosome 6 have been reported to occur in breast cancer, but little is known about the clinical relevance of this alteration.METHODS: We made use of a pre-existing tissue microarray with 2197 breast cancers and employed a 6q15/centromere 6 dual-labeling probe for fluorescence in situ (FISH) analysis RESULTS: Heterozygous 6q15 deletions were found in 202 (18%) of 1099 interpretable cancers, including 19% of 804 cancers of no special type (NST), 3% of 29 lobular cancers, 7% of 41 cribriform cancers, and 28% of 18 cancers with papillary features. Homozygous deletions were not detected. In the largest subset of NST tumors, 6q15 deletions were significantly linked to advanced tumor stage and high grade (p < 0.0001 each). 6q deletions were also associated with estrogen receptor negativity (p = 0.0182), high Ki67 proliferation index (p < 0.0001), amplifications of HER2 (p = 0.0159), CCND1 (p = 0.0069), and cMYC (p = 0.0411), as well as deletions of PTEN (p = 0.0003), 8p21 (p < 0.0001), and 9p21 (p = 0.0179). However, 6q15 deletion was unrelated to patient survival in all cancers, in NST cancers, or in subsets of cancers defined by the presence or absence of lymph-node metastases.CONCLUSION: Our data demonstrate that 6q deletion is a frequent event in breast cancer that is statistically linked to unfavorable tumor phenotype and features of genomic instability. The absence of any prognostic impact argues against a clinical applicability of 6q15 deletion testing in breast cancer patients.

AB - BACKGROUND: Deletions involving the long arm of chromosome 6 have been reported to occur in breast cancer, but little is known about the clinical relevance of this alteration.METHODS: We made use of a pre-existing tissue microarray with 2197 breast cancers and employed a 6q15/centromere 6 dual-labeling probe for fluorescence in situ (FISH) analysis RESULTS: Heterozygous 6q15 deletions were found in 202 (18%) of 1099 interpretable cancers, including 19% of 804 cancers of no special type (NST), 3% of 29 lobular cancers, 7% of 41 cribriform cancers, and 28% of 18 cancers with papillary features. Homozygous deletions were not detected. In the largest subset of NST tumors, 6q15 deletions were significantly linked to advanced tumor stage and high grade (p < 0.0001 each). 6q deletions were also associated with estrogen receptor negativity (p = 0.0182), high Ki67 proliferation index (p < 0.0001), amplifications of HER2 (p = 0.0159), CCND1 (p = 0.0069), and cMYC (p = 0.0411), as well as deletions of PTEN (p = 0.0003), 8p21 (p < 0.0001), and 9p21 (p = 0.0179). However, 6q15 deletion was unrelated to patient survival in all cancers, in NST cancers, or in subsets of cancers defined by the presence or absence of lymph-node metastases.CONCLUSION: Our data demonstrate that 6q deletion is a frequent event in breast cancer that is statistically linked to unfavorable tumor phenotype and features of genomic instability. The absence of any prognostic impact argues against a clinical applicability of 6q15 deletion testing in breast cancer patients.

U2 - 10.1007/s12282-021-01301-5

DO - 10.1007/s12282-021-01301-5

M3 - SCORING: Journal article

C2 - 34625909

VL - 29

SP - 216

EP - 223

JO - BREAST CANCER-TOKYO

JF - BREAST CANCER-TOKYO

SN - 1340-6868

IS - 2

ER -